# eXCIte<sup>osa</sup>

# Email Template to Send to Patient Database

This Patient Email Template is provided to assist you in educating your patient database on the availability of eXciteOSA<sup>®</sup>, a new FDA authorized daytime therapy for the reduction of mild obstructive sleep apnea and snoring.

# Hi [Patient Name]:

Begin your journey towards better sleep by learning more about a new daytime therapy option, eXciteOSA®.

eXciteOSA<sup>®</sup> is the world's first daytime therapy that is FDA authorized for reducing mild obstructive sleep apnea (OSA) and snoring. eXciteOSA<sup>®</sup> targets the root cause of mild OSA and snoring – the loss of muscle tone of the tongue – rather than simply relieving the symptoms.



## Daytime use for nighttime results

eXciteOSA<sup>®</sup> is the only daytime solution clinically proven to help with mild OSA and snoring. The non-invasive device only needs to be worn for 20 minutes a day, 1 time each day, for 6 weeks. Therapy is only required twice a week thereafter.

#### Easy to use

The smartphone app seamlessly connects to your eXciteOSA<sup>®</sup> device, making it easy to complete therapy sessions and track progress.

### **Clinically proven**

- 90% of patients reported a reduction in snoring time<sup>3</sup>
- 89% of bed partners reported a reduction of their partners snoring<sup>3</sup>
- 79% of sleep apnea patients achieved a reduction in sleep apnea measures<sup>3</sup>

Join the eXciteOSA<sup>®</sup> movement and learn more on how this daytime therapy is revolutionizing the way mild OSA and snoring are being reduced.

#### Learn more here [link to your website/call a phone #]

#### REFERENCES

1. E. Wessoleck et al. Intraoral electrical muscle stimulation in the treatment of snoring. Somnologie (Berl). 2018; 22(Suppl 2): 47–52 2. A. Sama et al. Daytime Intraoral Neurostimulation with Snoozeal® for treatment of Snoring and Mild Sleep Apnea. CHEST Annual Meeting Notes, 2018 3. eXciteOSA® White Paper (2020). Clinical study of 115 patients with snoring or mild OSA (Apnea- Hypopnea Index (AHI) <15 n=65) completed the trial. Objective snoring and respiratory parameters were recorded with 2 consecutive WatchPAT® night sleep studies before and after the use of the device. An intra- oral tongue stimulator device was used for 20 mins, once a day for 6-week period. (Internal publication by SMT for educational purposes and submission.)



Signifier Medical Technologies LLC 175 Highland Avenue Needham, MA 02494 USA +1 844 MildOSA | info@signifiermedical.com www.exciteOSA.com